Please provide your email address to receive an email when new articles are posted on . The FDA has granted a prior approval supplement to Zydus Lifesciences Limited allowing the company to market its ...

Please provide your email address to receive an email when new articles are posted on . Tacrolimus alone had a dose-response relationship with achieving complete renal response in SLE. Combination ...

Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...

Researchers conducted a retrospective analysis of 1435 patients with limited cutaneous SSc from the Italian SPRING registry to assess the purpose of starting mycophenolate mofetil treatment and its ...

† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females represented ...

CellCept (mycophenolate mofetil) is a prescription drug that’s used to help prevent organ rejection after an organ transplant. The most common side effects reported with CellCept include diarrhea and ...

LONDON, Dec 14 (Reuters) - The European Medicines Agency has recommended approval of Teva Pharmaceutical Industries Ltd's generic versions of the organ rejection drug CellCept, the watchdog said on ...

ATLANTA — New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, demonstrated that withholding mycophenolate mofetil for at least 10 days ...

In a new analysis of the BLISS LN trial, researchers added Belimumab (Benlysta) to Mycophenolate (MMF), the standard of care treatment for lupus nephritis, (LN, lupus-related kidney disease) and found ...

Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...

Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted. Mycophenolate mofetil (MMF) reduces the risk of disease progression in patients with immunoglobulin A ...

Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: Phase I clinical trial results. Use of lucicebtide (ST101) in glioblastoma patients by antagonism of ...